TPWA
CRVS icon

Twin Peaks Wealth Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7
Closed -$102 – 668
2026
Q1 		$102 Buy
+7
New +$112 ﹤0.01% 2240

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Twin Peaks Wealth Advisors's CRVS Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Corvus Pharmaceuticals (CRVS) in Q2 2026, closing a stake of 7 shares — an estimated $102 sold.

Twin Peaks Wealth Advisors first reported a position in CRVS in Q1 2026 and held it in 1 quarter. The position peaked at $102 in Q1 2026. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Corvus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 7 Corvus Pharmaceuticals shares in Q2 2026, an estimated $102.
  • Twin Peaks Wealth Advisors first reported a position in Corvus Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Twin Peaks Wealth Advisors's Corvus Pharmaceuticals position peaked at $102 in Q1 2026.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.